Waters Corporation (WAT) has been a hot topic recently, with a lot of significant events and announcements affecting its business. Recently, expectations are high for WAT's
Q3 earnings with its stock price target raised to $400 from $390 at
TD Cowen. WAT has unveiled a new empower-ready CAD system, secure pre-orders, and is primed to ship by April 2026. It has also raised its
annual profit forecast due to increased demand for lab equipment. Furthermore, WAT is set to present at the Jefferies Global Healthcare Conference in London. On the innovation front, WAT launched
Charge Detection Mass Spectrometry Technology to prompt the development of next-gen biotherapeutics. Following the acquisition announcement, WAT stock slipped, leading to market underperformance. In Q3 2025, WAT reported
strong revenue growth and raised guidance, even as it announced a merger with BD's Biosciences and Diagnostic Solutions Business. This strategic merger is expected to cumulate a life science and diagnostics leader focusing on regulated, high-volume testing. Significant ups and downs in WAT's stock were observed, with various factors accountable, including earnings expectation beating, acquisition announcement, weak performance, and
strong fundamentals.
Waters Corp WAT News Analytics from Wed, 12 Feb 2025 08:00:00 GMT to Fri, 14 Nov 2025 14:51:00 GMT -
Rating 6
- Innovation 4
- Information 7
- Rumor -3
